Study of XNW27011 for advanced solid tumors that failed standard therapy
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called XNW27011 for people with advanced solid tumors that have not responded to standard therapies. It may be especially relevant for tumors that have a specific protein called CLDN18.2, but it is not required for the first part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (like stomach, pancreatic, ovarian, lung, colorectal, or bile duct cancer) that has stopped responding to standard treatments or you cannot take them.
- You are able to do daily activities with little help (ECOG score 0-2).
- Your major organs (blood cells, liver, kidneys, heart) are working well enough, based on blood tests and heart tests.
- If you have had treatments before, enough time has passed since your last dose (at least a few weeks, depending on the type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW28012 for people with advanced solid tumors that have not responded to or caused side effects from standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called XNW34017 for people with advanced solid tumors, including small cell lung cancer and prostate cancer. It may be an option if you've tried other treatments that no longer work.
This trial tests a new drug, XNW28012, for people with metastatic pancreatic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug is safe and helps control the cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.